A group of tardive dyskinesia experts has concluded that individuals taking antipsychotics should receive regular assessments, tardive dyskinesia may be indicated by mild movements isolated to 1 body area, an overall assessment of treatment is required for management, and thorough caregiver/patient discussions are required.
A study found a link between D2 receptor blockade, BOLD signal normalization, and treatment response in patients with schizophrenia.
The update was prompted by an FDA review of 10 cases of constipation in clozapine-treated patients that resulted in serious complications.
The FDA has accepted for review the New Drug Application (NDA) for ALKS 3831 (Alkermes) for the treatment of schizophrenia and bipolar I disorder.
Among patients with schizophrenia, long-term antipsychotic use does not appear to increase severe physical morbidity or somatic hospitalization, and mortality is lower for antipsychotic use compared with no use.
The findings suggest that factors such as antipsychotic treatment, diet, or lifestyle may contribute to weight gain in patients with long-term disease.
Current antipsychotic therapy, effective primarily for positive symptoms but limited with negative symptoms, may be related to serious adverse effects, including motor impairments, prolactin abnormalities, and cardiometabolic disturbances.
The researchers noted that recent stressful life events, perceived stress, daily cortisol levels, and high sensitivity C-reactive protein levels accounted for 78% of the variance between women with postpartum psychosis and healthy controls and 46% of the variance between at-risk women and healthy controls.
Symptom reduction was significantly correlated with poor metabolic adverse effects, including weight gain, elevated BMI, and higher total cholesterol.
The investigators recommended revising the CAPE-P15 cutoff thresholds to 1.30 and 1.29 for the frequency and distress subscales, respectively. These cutoff values have high sensitivity for psychotic experiences.